Last reviewed · How we verify
LY3295668
At a glance
| Generic name | LY3295668 |
|---|---|
| Also known as | AK-01, Erbumine |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer (PHASE1, PHASE2)
- A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma (PHASE1)
- A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer (PHASE1)
- A Study of AK-01 (LY3295668) in Solid Tumors (PHASE1, PHASE2)
- A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3295668 CI brief — competitive landscape report
- LY3295668 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI